For patients with positive margins, I perform both cytology and colposcopy in 4 to 6 months. If an endocervical margin was positive, I also perform an ECC. If this evaluation is negative, I repeat cytologic testing every 6 months until 3 consecutive Pap smears are normal and satisfactory. In cases of recurrent high-grade dysplasia with positive margins, hysterectomy may be indicated, depending on the patient’s age and desire for continued fertility.14,21
Squamous microinvasion
There is a significant risk (50%-80%) of residual disease or true invasion when margins or an ECC are positive and microinvasion is present.2,5-7 In these cases, a repeat excisional biopsy should be performed to determine the true extent of disease prior to deciding on definitive therapy.22 As previously mentioned, CKC is preferred to limit artifact that could obscure interpretation. If the patient has completed her childbearing, hysterectomy remains the standard treatment for microinvasive squamous cell carcinoma. When the woman wishes to preserve fertility, conservative follow-up appears to be safe if the final pathologic specimen has negative margins. A follow-up protocol including cytologic, colposcopic, and ECC monitoring in the first post-conization visit is recommended.2,6
Glandular lesions
AIS with involved margins requires further surgery due to the possibility of residual AIS or invasion (TABLES 2 and 3).2,5-7 In these cases, CKC is preferable to LEEP.3,5-7 Hysterectomy remains the standard therapy for AIS. Conservative management is an option if fertility is desired and margin status is negative. Patients should be informed that persistent disease or recurrence is possible and that there is a risk of invasive disease.15
Counseling, thorough documentation, and second surgical and pathologic opinions may be helpful in conservative management. Colposcopy, ECC, and cytology are indicated at the first follow-up visit, with cytology repeated every 6 months until 4 consecutive Paps are normal. More frequent colposcopy and liberal use of ECC also may be considered.
TABLE 2
Residual disease and margin status: adenocarcinoma in situ
AUTHOR | PROPORTION WITH RESIDUAL DISEASE | |||
---|---|---|---|---|
NEGATIVE MARGINS | POSITIVE MARGINS | |||
NUMBER | % | NUMBER | % | |
Azodi et al, 199928 | 5/16 | 31.3 | 9/16 | 56.3 |
Goldstein et al, 199828 | 13/43 | 30.2 | 8/18 | 44.4 |
Denehy et al, 19976 | 2/7 | 28.6 | 7/10 | 70 |
Widrich et al, 19965 | 0/3 | 0 | 9/14 | 64.3 |
Wolf et al, 199629 | 7/21 | 33.3 | 10/19 | 52.6 |
TOTAL | 27/90 | 30 | 43/77 | 55.8 |
TABLE 3
Follow-up recommendations
Pathology | Margin status | Recommendation |
---|---|---|
High-grade squamous lesion | Negative |
|
Positive, endocervical |
| |
Positive, ectocervical |
| |
Squamous microinvasion | Negative, fertility desired |
|
Negative, no desire for fertility | Hysterectomy | |
Positive | CKC | |
Adenocarcinoma in situ | Negative, fertility desired |
|
Negative, no desire for fertility | Hysterectomy | |
Positive | CKC | |
CKC = cold-knife conization; ECC = endocervical curettage |
When further excision is necessary
As noted earlier, repeat excision is necessary in cases of squamous microinvasion or AIS with positive margins. CKC is generally preferred to allow for optimal pathologic interpretation. For squamous intraepithelial lesions, excisional biopsy with close follow-up has a significant cure rate, and hysterectomy usually is not indicated. However, hysterectomy still should be considered part of the treatment continuum for CIN, particularly for patients who have completed childbearing.
Conclusion
Although the risk of recurrence is correlated with a patient’s margin status in cases of squamous dysplasia, conservative follow-up is possible and has a high success rate. Cytology is sufficient surveillance for cases involving negative margins. When margins are positive, colposcopy and ECC also may be useful. Microinvasive lesions with positive margins require further surgical evaluation to determine treatment. For glandular lesions, CKC is preferred for both diagnosis and treatment.
Dr. Dunton reports no affiliation or financial arrangement with any of the companies that manufacture drugs or devices in any of the product classes mentioned in this article.